266 related articles for article (PubMed ID: 32704022)
1. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.
Lee YJ; Seo HW; Baek JH; Lim SH; Hwang SG; Kim EH
Sci Rep; 2020 Jul; 10(1):12272. PubMed ID: 32704022
[TBL] [Abstract][Full Text] [Related]
2. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
[TBL] [Abstract][Full Text] [Related]
3. Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines.
Jeong H; Jo Y; Yoon M; Hong S
Genes Genomics; 2021 Sep; 43(9):995-1001. PubMed ID: 33950471
[TBL] [Abstract][Full Text] [Related]
4. Theory and application of TTFields in newly diagnosed glioblastoma.
Yu A; Zeng J; Yu J; Cao S; Li A
CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
[TBL] [Abstract][Full Text] [Related]
5. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of tumor treating fields for malignant brain tumors.
Zhou Y; Xing X; Zhou J; Jiang H; Cen P; Jin C; Zhong Y; Zhou R; Wang J; Tian M; Zhang H
Cancer Rep (Hoboken); 2023 May; 6(5):e1813. PubMed ID: 36987739
[TBL] [Abstract][Full Text] [Related]
7. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
8. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
[TBL] [Abstract][Full Text] [Related]
9. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions.
Simchony H; Diamant D; Ram Z; Volovitz I
Isr Med Assoc J; 2019 Jul; 21(7):503. PubMed ID: 31507132
[TBL] [Abstract][Full Text] [Related]
11. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
12. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
13. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
14. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
15. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
16. Alternating Electric Fields (TTFields) Activate Ca
Neuhaus E; Zirjacks L; Ganser K; Klumpp L; Schüler U; Zips D; Eckert F; Huber SM
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669316
[TBL] [Abstract][Full Text] [Related]
17. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
19. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma.
Xu S; Luo C; Chen D; Tang L; Chen L; Liu Z
Cell Death Dis; 2022 Aug; 13(8):721. PubMed ID: 35982032
[TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
